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ABSTRACT  
Primary liver cancer is the sixth most frequent and the second most deadly cancer worldwide and 
the global epidemic of non-alcoholic fatty liver disease is expected to severely impact on the 
epidemiology of this cancer. Due to the limited availability of effective chemotherapeutic agents, 
novel bioactive molecules are urgently required.  To address this, two series of boehmeriasin A 
analogs have been synthesized in short and high yielding processes providing derivatives 
differing either in the alkaloid’s pentacyclic scaffold or its peripheral substitution pattern. These 
series have enabled, for the first time, comparative studies into key biological properties 
revealing a new lead compound with exceptionally high activity against liver cancer cell lines in 
the picomolar range for both well (Huh7, Hep3B and HepG2) and poorly (Mahlavu, FOCUS and 
SNU475) differentiated cells.   The cell death, induced by the compounds 1 and 19, was 
characterized as apoptosis by cytochrome-C release, PARP protein cleavage and SubG1 cell 
cycle arrest. Subsequent testing associated apoptosis via oxidative stress with in situ formation of 
ROS and altered phosho-protein levels. Compound 19 decreased Akt protein phosphorylation 
which is crucially involved in liver cancer tumorigenesis. Given its simple synthetic accessibility 
and the intriguing biological properties of our new lead compound this has unique potential to 
address unmet challenges within liver cancer therapy. 
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Introduction 
Primary liver cancer (hepatocellular carcinoma, HCC), is the sixth most frequent cancer type 
and the second highest cause of cancer-related death worldwide [1]. Viral infections with 
hepatitis B or C, alcoholic injury, obesity and other factors inducing cirrhosis and chronic liver 
disease are the major risk factors for HCC [2-4]. It is also expected that the rate of liver cancer 
and associated deaths will increase in the coming years due to the global epidemic of non-
alcoholic fatty liver disease (NAFLD) [5].   Despite the well-known etiological factors, liver 
cancer remains one of the most lethal types of cancer, due to very limited therapeutic options 
with significant clinical benefits [6]. Liver resection, transplantation and chemoembolization are 
still the most amenable options to remedy, however, not all the patients meet the criteria for these 
treatments [7]. Meanwhile, patients with advanced HCC suffer from the lack of effective 
therapy. The first FDA approved drug Sorafenib (5, Figure 1), which is a multi-kinase inhibitor, 
can only improve patients’ median survival for about 3 months [8].  Very recently the closely 
related multi-kinase inhibitor Regorafenib was used in patients as a second line treatment. The 
mean survival was about 10 months compared to a placebo (~8 months) [9]. 
To address these challenges in the arena of liver cancer [10], we decided to investigate the 
chemical synthesis and biological evaluation of new analogs of the known plant alkaloid 
boehmeriasin A. 
Boehmeriasin A (1, Figure 1) is a pentacyclic phenanthroquinolizidine alkaloid recently 
isolated from the ethanolic extract of boehmeria siamensis Craib [11], a plant that has long been 
used in south-east Asia for the treatment of rheumatism as well as skin diseases such as urticaria 
(hives). Upon extensive biological studies, it was revealed that 1 possesses significant activity 
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against several cancer cell lines commonly exceeding the potency of Taxol by at least tenfold. 
The nanomolar cytotoxic activity of boehmeriasin A was established for various cancer cells, 
originating from lung, colon, breast, prostate, kidney cancers, and leukemia [12]. In addition to 
this anti-cancer activity boehmeriasin A also causes G1 cell cycle arrest, cellular differentiation, 
affects cellular morphology and results in lipid droplet accumulation in breast cancer cells [13]. 
It was furthermore found that boehmeriasin A shares this promising anti-cancer activity with 
other members of the phenanthroquinolizidine and -pyrrolizidine alkaloids such as tylophorine 
(2), antofine (3) and cryptopleurine (4) (Figure 1) [14-21].  
 
Figure 1: Structures of racemic boehmeriasin A 1, related alkaloids (2-4) and sorafenib (70%). 
Driven by the promising bioactivity reports, many successful total syntheses of these intriguing 
cytotoxic alkaloids have been disclosed [12,22-24].  Despite these efforts neither the molecular 
target nor the mode of action of these important structures have been identified and detailed SAR 
studies are lacking, which does severely hamper further progress in the development towards 
boehmeriasin A based drug leads. To establish this missing key data, we wished to evaluate 
boehmeriasin A as well as several new analogs in the context of human epithelial cancers 
especially in liver cancer.  
Analog Synthesis: Upon analysis of the parent pentacyclic scaffold of boehmeriasin A (1) and 
its closely related natural products (2-4) we decided to design and synthesize two series of target 
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compounds to study structure-activity relationships of these entities. Thus, a first series would 
retain the oxygenation pattern of boehmeriasin A but introduce alterations in the connectivity of 
the fused ring system, whereas in a second series the pentacyclic framework would be conserved 
while modifications to the embedded quinolizidine system would be made. 
To create these two series, we decided to exploit a synthetic route to boehmeriasin A itself which 
we had developed previously (Scheme 1) [24]. This route is based on an efficient 7-step 
sequence in which a Perkin reaction is followed by an esterification to yield building block 8 that 
was then converted into the phenanthrene unit 9 by a FeCl3-mediated oxidation. The pendant 
ester functionality was reduced to an alcohol and activated as a chloride (10) to then allow 
coupling with pipecholic acid (11). Subsequent treatment of 12 with polyphosphoric acid (PPA) 
led to ring closure via a Friedel-Crafts acylation reaction and furnished ketone 13 that upon full 
reduction rendered the desired natural product 1. This approach was deemed very attractive as it 
is robust and scalable and furthermore allows to introduce desirable variations on different 
moieties of the parent structure of 1. 
 
Scheme 1: Previous synthesis of racemic boehmeriasin A (1). 
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The synthesis of the first series of analogs made use of intermediates 8 and 9 that were 
independently elaborated by amide coupling with aminopropyl imidazole (14, Scheme 2), which 
was chosen as a hydrophylic appendage to mimic the quinolizidine substructure of 1 and at the 
same time improve the bioavailability of these species. Furthermore, it was intended to modulate 
the planarity of the phenanthrene system by omitting the central C-C bond in some of the 
analogs, which would enable us to evaluate the likelihood of these entities to act via DNA 
interchelation. 
 
Scheme 2: Synthesis of analogs 15-18 (Series 1). 
To this end both 8 and 9 were hydrolyzed under basic conditions rendering the corresponding 
carboxylic acid derivatives, that were subsequently activated by CDI and coupled with 
aminopropyl imidazole (14) to furnish the desired amides 15 and 16 in good yield. In addition, 
both amides were treated with LAH (2.5 equiv.) to obtain the corresponding amines 17 and 18 
allowing to establish the effect of having an amide versus an amine incorporated into these 
structures, which could have implications due to altered H-bonding patterns. 
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With selected examples of a first analog series in hand we turned our attention to a second series 
in which we envisaged to study alterations on the pentacyclic framework of boehmerisain A. 
Specifically, we decided to explore manipulations on the carbonyl of 13 by means of its 
reduction to the corresponding alcohol derivatives. The synthesis of the desired alcohols was 
readily accomplished by reduction of 13 by LAH (2.0 equiv.) giving a mixture of diastereomeric 
alcohol products 19a and 19b in a 1:2 ratio. Pleasingly, as it was possible to separate this mixture 
by preparative TLC we were able to undertake characterization and subsequent biological 
evaluation of the individual diastereomers. Additionally, single crystal X-ray diffraction 
experiments were used to identify the major diastereomer 19b as the trans-alcohol product 
(Scheme 3).   
 
Scheme 3: Synthesis of analogs 19a and 19b from ketone 13 (Series 2). 
Together with boehmeriasin A (1) and its carbonyl derivative 13, these individual alcohol 
derivatives 19a and 19b therefore represent the second series of analogs available for detailed 
biological testing (Figure 2). 
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Figure 2: Overview of both series of new boehmeriasin A analogs. 
Biological Studies:  
2.1 Biological Activities of First Series of Boehmeriasin A Analogs 
Commencing our studies with boehmeriasin A analogs 15-18 we analyzed their cellular toxicity 
against different hepatocellular carcinoma cells, namely Huh7 and Mahlavu. As pointed out 
earlier we wished to establish whether simplified structures possessing a conformationally open 
ring system would still impart significant cytotoxicity, whilst improving solubility by 
introduction of an imidazole appendage. However, to our surprise it was found that these analogs 
displayed either very moderate activity (compounds 16 and 17 IC50 10-54 μM) or no activity 
(compounds 15 and 18, Table 1). Additionally, the presence of an amide or amine linkage as 
well as the central biaryl bond appears to be irrelevant for any activity against these cell lines. 
Whilst somewhat unexpected this finding establishes clearly that the pentacyclic framework of 
the boehmeriasins is crucial for their sub-micromolar biological activity which had not been 
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demonstrated before. This furthermore highlights the importance of the embedded quinolizidine 
substructure and prompted us to evaluate analogs of our second series next. 
Table 1: Cytotoxicity of compounds 15-18 evaluated in HCC cells. 
IC50 Values (µM) 
Compound Huh7 Mahlavu 
15 NI NI 
16 19.2 54 
17 9.3 13.8 
18 NI NI  
*NI: No inhibition 
 
2.2 Cytotoxicity of Second Series of Boehmeriasin A Derivatives  
To verify the anticipated biological activity of the parent boehmeriasin A (1) and its analogs (12, 
13, 19) an initial screen against different epithelial cancer cells, namely liver (Huh7), breast 
(MCF7) and colon (HCT116) carcinoma cells was performed. The cytotoxicity of each 
compound was assessed by sulforhodamine B (SRB) assay. IC50 values of the synthesized 
compounds were calculated for each cell line following 72 hours of treatment (Table 2).  
 
Table 2: Initial screening of compounds 1, 12, 13 and 19.  
IC50 Values (µM) 
Compound Huh7 MCF7 HCT116 
1  0.008 0.005 0.7 
19  0.002 0.001 < 0.001 
12  NI NI NI 
13  12 7 8.1 
*NI: No inhibition 
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In general, boehmeriasin A (1) and its hydroxy analog 19 (as 1:2 mixture of diastereomers) were 
identified as promising anti-cancer compounds due to their low nanomolar IC50 values. Although 
ketone derivative 13 showed moderate cytotoxicity, when compared to 1 and 19 its bioactivity 
was low despite the only minor alteration of its structure. Additionally, the carboxylate species 
12 had no cytotoxic bioactivity against these cancer cells, possibly as it does not easily permeate 
into cells due to its nature being a salt. Furthermore, this result is in line with the loss of activity 
seen for the other ‘open-structured’ analogues 15-18.  
Considering the lack of HCC targeted chemotherapeutic agents and based on our specific aim in 
this study, we furthermore tested these compounds (1, 12, 13 and 19) against various liver cancer 
cell lines. Therefore, we assessed the IC50 values of these compounds in a HCC cell panel (Huh7, 
Mahlavu, SNU475, FOCUS, Hep3B and HepG2) (Table 3).  
Table 3: Cytotoxicity of compounds in HCC cell panel. 
 
IC50 Values (µM) 
 
Huh7 Hep3B HepG2 Mahlavu SNU475 FOCUS Compound 
 
  
 
  
   1 0.008 0.016 0.06 0.016 0.014 0.02 
19 0.002 0.017 2.7 ± 0.9 0.01 0.015 0.012 
12 NI NI NI NI NI NI 
13 12 45 NI 35 19.1 5 
*NI: No inhibition 
 
Similarly to our results presented in Table 2, compounds 1 and 19 were found to be significantly 
cytotoxic in all cell types of HCCs. Crucially, 1 and 19 displayed nanomolar IC50 values not only 
for well differentiated HCC cells such as Huh7, Hep3B and HepG2 but also for poorly 
differentiated and more aggressive cells which are Mahlavu, FOCUS and SNU475. Therefore, 1 
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and 19 can be considered potential anti-cancer drug candidates in liver cancer cells. On the other 
hand, 13 displayed limited cytotoxic activity and 12 had no activity in any type of HCC cells.  
 
2.3. Real-time assessment of hepatocellular carcinoma cell growth upon treatment with 
compounds 1 and 19  
A real-time cell electronic sensing (RT-CES) assay was used to evaluate the bioactivities of 
boehmeriasin A and its analogs on well differentiated Huh7 cells and poorly differentiated 
Mahlavu cells. According to the data obtained from RT-CES, the time dependent IC50 values 
were calculated (Table 4). In general, the RT-CES results support the findings of the above SRB 
assay. Candidates 1 and 19 caused severe growth inhibition in both Huh7 and Mahlavu cells 
(Figure 3). The real-time growth inhibition pattern suggested a cell cycle arrest in cells treated 
with 1 and 19, as DMSO treated cells retain their proliferation profile until they become 
confluent (2).  
 
Table 4: Time dependent IC50 values of compounds 1 and 19. 
IC50 Values (µM) 
Compound Huh7 Mahlavu 
24 h 48 h 72 h 24 h 48 h 72 h 
1 2 µM 1 µM 0.8 µM 0.6 µM 0.5 µM 0.6 µM 
19 1.9 µM 0.8 µM 0.6 µM 0.4 µM 0.1 µM 0.1 µM 
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Figure 3: Real-time cellular proliferation assay. RT-CES analysis of Huh7 and Mahlavu cell lines treated 
with various concentrations of the compounds 1 and 19. Blue: 1 M, Red: 0.5 M, Black: 0.25 M, 
Green: 0.125 M. DMSO is used as solvent control and percent cell growth data is normalized according 
to DMSO controls.  
The curvature of our real time cell death data and the measured IC50 values imply that the cell 
death associated with these compounds could be apoptosis.  The differences of IC50 values 
between SRB end point colorimetric assay and the RT-CES can be due to the evaluation of 
distinct cellular elements. While SRB detects the total protein levels, RT-CES is dependent on 
the cell surface attachment.  During apoptosis there is a high destruction of cellular proteins 
which leads to less colorimetric data collection. Therefore, it is common to observe IC50 
differences between cell death detection techniques. Hence in this study, we established the 
bioactivities of the new boehmeriasin A analogs with two complementary techniques.  
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2.4. Characterization of Cell Death Mechanism Induced by Boehmeriasin Derivatives 
The cell death mechanism of the cells treated with boehmeriasin A or its derivatives was initially 
analyzed by observing the release of cytochrome-C which was examined via fluorescence 
microscopy (Figure 4A). Camptothecin (CPT) was used as positive control for cytochrome-C 
release, showing that cytochrome-C levels in cells treated with 1 and 19 were comparable to the 
positive control. A significant increase in the release of cytochrome-C in cells treated with 1 and 
19 indicates apoptotic cell death. 
The activation of apoptotic pathways by boehmeriasin A derivatives was further studied by 
evaluating the status of one the most well-known apoptotic proteins, PARP. Here a significant 
increase in PARP cleavage in the cells treated with 19 was identified and did become significant 
within 72 h in cells. Compared to boehmeriasin A itself, its hydroxy-derivative 19 displayed a 
more significant effect on PARP cleavage that is paralleled by its increased cytotoxic effect on 
liver cancer cells (Figure 4B).  
A 
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B
 
Figure 4: Analysis of apoptotic processes in cells treated with Boehmeriasin A derivatives. (A) The 
evaluation of Cytochrome C release in Huh7 and Mahlavu cells treated with 1 M 1 and 19. (B) PARP 
cleavage in Huh7 and Mahlavu cells treated with 1 M 1 and 19 for 24 and 72 hours. DMSO is used as 
solvent control.  
 
2.5.  Cell Cycle Analysis of HCC Cells treated with Boehmeriasin Derivatives  
To identify the effect of boehmeriasin derivatives on the cell cycle progress flow cytometry 
analysis was performed using propidium iodide (PI) staining in Huh7 and Mahlavu liver cancer 
cells. Upon treatment with 1 and 19, increasing levels of apoptotic cells along with SubG1 arrest 
were observed. The most significant increase was observed at 72 h.  19 resulted in the higher 
number of cells that accumulated at SubG1 phase. Additionally, HCC cells treated with 1 also 
led to an increase in SubG1, however this effect became more notable after 72 h (Figure 5 A, B). 
In addition, the effect of boehmeriasin A derivatives on the cell cycle was further investigated in 
Huh7 and Mahlavu cell by western blot analysis of the proteins which are involved in this 
process. 1 and 19 down-regulated Cyclin B1 (CDK1 regulator and mitotic initiator in the late G2 
phase) and its companion CDK1 (essential for G1/S and G2/M phase transitions) levels in Huh7 
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cells. Treatment with 1 and 19 also reduced the CDK2 (G1 to S phase transition) and its 
regulator Cyclin E level, which became more significant at 72h. Altogether, these results indicate 
that boehmeriasin A derivatives induce cell cycle arrest at G2/M and SubG1 phases which is 
followed by apoptosis in these cells (Figure 5A). 
The effect of these compounds on cell cycle protein expression is more pronounced on Huh7 
cells (Figure 5B). Mahlavu cells are reported as more resistant to small molecule inhibitors due 
to PTEN deletion in PI3K/Akt signaling pathway [25]. The effect of the compounds can still be 
observed even in these cells. Furthermore, the active phosphorylated form of Akt protein is 
significantly down-regulated with compound 19 at 72 hours (Figure 5B).  
A
 
B 
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Figure 5: The assessment of the cell cycle status of cells treated with boehmeriasin A derivatives (A) The 
time dependent cell cycle analysis of treated Huh7 and Mahlavu cells with flow cytometry (B) 
Comparative analysis cell cycle protein expression in the presence of 1 and 19. DMSO is used as solvent 
control. 
 
2.6. Release of Reactive Oxygen Species and Stress Mechanism Induced by Boehmeriasin 
Derivatives 
Reactive oxygen species (ROS), depending on their dose, can alter cellular pathways and 
promote cell cycle arrest and apoptosis in liver cancer cells [25]. The released ROS can be 
visualized using the 2,7-dichlorofluorescein diacetate (DCFH-DA) assay. The presence of 
fluorescence stain, which is detected via fluorescence microscopy, indicates ROS activity and 
thus cellular stress. Evaluating the presence of ROS in liver cancer cells that were treated with 
boehmeriasin A and its derivatives showed that the ROS activity in cells treated with 1 and 19 
was significantly increased and became comparable to the positive control. The ROS activity 
increased with time of incubation of 1 and 19 (Figure 6A).  
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In addition, as boehmeriasin analogs induced oxidative stress, these were assessed by evaluating 
the phosphorylation status of the proteins involved in the ROS pathway via western blot [5]. It 
was found that both Mahlavu and Huh7 cells treated with 1 and 19 led to a decrease of the 
phosphorylated Ser-966-ASK1 levels which is associated with cellular oxidative stress, though 
the effect on Mahlavu is being more prominent [5] (Figure 6B). Mahlavu cells are characterized 
by a hyperactive PI3K/AKT pathway due to PTEN protein deletion and therefore we observe 
differential downstream P-SAPK/JNK protein levels. The stress protein SAPK/JNK 
phosphorylation was increased in Huh7 cells treated with both 1 and 19. In Mahlavu cells the P-
SAPK/JNK levels were differentially altered with 1 and 19 treatments in parallel to AKT 
phosphorylation status.  The compound 19 decreases the p-AKT levels which is the active from 
of this protein for cell survival. Our data indicates that the novel compound 19 gains its 
intriguing bioactivity through PI3K/AKT pathway modulation which is strategically involved in 
liver cancer tumorigenesis.  
 
A 
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B
 
Figure 6: The analysis of cellular stress mechanism. (A) The evaluation of ROS activity by DCHF-DA 
staining in Huh7 cells treated with boehmeriasin derivatives. DCFH-DA is cell permeable dye, and, after 
uptake, it is cleaved by intracellular esterases to 2,7-dichlorodihydrofluorescin (DCFH2), which is 
trapped within the cells, and is oxidized to fluorescent 2,7-dichlorofluorescein (DCF) in the presence of 
ROS. The cells that grow in serum free medium were shown to induce ROS activity, therefore, we used 
serum free culture media as positive control. (B) The western blot analysis of the stress related proteins of 
boehmeriasin derivatives treated Huh7 and Mahlavu cells. 
 
2.7.  The bioactivity of Individual Hydroxy-Analogs 19a and 19b in HCC cells  
After concluding that 19 (as a 1:2 mixture of diastereomers 19a and 19b) possessed the highest 
bioactivity, we decided to further study its individual diastereomers to establish whether a 
preference of the relative stereochemistry manifests in differentiated activity. The separation of 
this mixture of diastereomers was accomplished by preparative thin layer chromatography 
yielding 19a as the minor (lower Rf) and 19b as the major (higher Rf) diastereomer in a 1:2 ratio. 
The individual hydroxy-analogs 19a and 19b were initially screened in human cancer cells 
(Table 5) and the data was verified with SRB assays confirming not only that both hydroxy-
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analogs were highly active anti-cancer compounds but moreover that 19b displayed superior 
activity in the picomolar range. 
Table 5: Cytotoxicity of compounds 19a and 19b evaluated in different human cancer cells. 
IC50 Values (nM) 
Compound Huh7 MCF7 HCT116 
19a (minor) 0.306 0.016 0.043 
19b (major) 0.017 0.021 0.007 
 
Correlating this intriguing finding with the single crystal X-ray structure secured for the major 
diastereomer 19b (see Scheme 3) demonstrates that the highest activity results from the 
diastereomer having the hydroxy substituent trans to the methine proton and syn to the ring 
nitrogen. Although, the reason of this is not entirely clear at this point this finding might point to 
a specific binding mode of 19b within its molecular target.  
Despite efforts in separating the racemic 19b by means of chiral HPLC so far having been 
unsuccessful, it is apparent that 19b is a very active boehmeriasin A derivative possessing 
picomolar anti-cancer activity against challenging breast, colon and liver cell lines which 
therefore warrants further investigations. We thus believe that this opens further avenues to 
elucidate the specific identity and binding mode of our novel drug-lead 19b to its molecular 
target. 
In conclusion, we have successfully prepared two sets of new boehmeriasin A analogs featuring 
either a simplified structure or a complete pentacyclic framework as found in the parent alkaloid. 
Whilst the former was found to be significantly less active (IC50 > 10 μM) than boehmeriasin A, 
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the latter series displayed superb anti-cancer activity across a range of cell lines. Minute 
structural changes from a ketone (13, H-bond acceptor) to a secondary alcohol (19, H-bond 
donor) have resulted in a 10,000-fold increase in activity, which is more pronounced in the trans-
diastereomer (19b) and surpasses the activity of boehmeriasin A itself. Subsequent in-depth 
biological studies have revealed a broad spectrum of activities including cell cycle arrest in the 
sub-G1 stadium, the generation of reactive oxygen species as well as the activation of apoptotic 
pathways through PARP cleavage. Due to the straightforward synthetic accessibility and the 
intriguing biological properties of our new lead compound 19b we foresee its potential for future 
developments to address unmet challenges within liver cancer therapy. 
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Experimental section 
3.1. Synthesis Procedures for New Compounds 
Rac.-Boehmeriasin A, 1 and 3,6,7-trimethoxy-12,13,14,14a-tetrahydro-9H-dibenzo[f,h]-
pyrido[1,2-b]isoquinolin-15(11H)-one, 13 were prepared as reported previously [24]. 
(E)-N-(3-(1H-Imidazol-1-yl)propyl)-2-(3,4-dimethoxyphenyl)-3-(4-methoxyphenyl)acryl-
amide, 15: To a solution of methyl (E)-2-(3,4-dimethoxyphenyl)-3-(4-methoxyphenyl)acrylate 
(8, 1.0 g, 3.05 mmol) in methanol (10 mL, 0.3 M) was added an aqueous solution of KOH (5.0 
M, 5 mL, 8.3 equiv. KOH). The resulting mixture was stirred at 50 °C for 4 h when tlc analysis 
indicated full conversion of 8. After neutralizing with aqueous HCl (1 M) and extraction 
(DCM/water, 2 x 50 mL) the organic layers were combined, dried over anhydrous sodium 
sulfate, filtered and evaporated to dryness under reduced pressure. The solid residue was 
redissolved in MeCN (15 mL) and combined with carbonyldiimidazole (CDI, 500 mg, 3.09 
mmol, 1 equiv.). After heating this mixture for 1 h at 50 °C aminopropylimidazole (275 mg, 3.0 
mmol, 1.0 equiv.) was added and the mixture was stirred at 50 °C for a further 2 h. After 
evaporation of the volatiles the crude product was extracted (DCM/water, 2 x 20 mL) and 
isolated as an off-white solid (1.0 g, 2.4 mmol, 78 %) after drying over anhydrous sodium 
sulfate, filtration, evaporation and trituration from cold ethyl acetate. 
1H-NMR (400 MHz, CDCl3): δ/ppm 7.68 (s, 1H), 7.34 (d, J = 1.2 Hz, 1H), 6.92 (d, J = 1.1 Hz, 
1H), 6.91 – 6.87 (m, 3H), 6.83 (d, J = 1.3 Hz, 1H), 6.72 (dd, J = 8.2, 1.9 Hz, 1H), 6.64 (d, J = 1.9 
Hz, 1H), 6.60 (d, J = 8.9 Hz, 2H), 5.73 (t, J = 6.1 Hz, 1H), 3.89 (t, J = 7.0 Hz, 2H), 3.86 (s, 3H), 
3.72 (s, 3H), 3.66 (s, 3H), 3.23 (app q, J = 6.7 Hz, 2H), 1.90 (app p, J = 6.9 Hz, 2H). 13C-NMR 
(100 MHz, CDCl3): δ/ppm 167.9 (C), 159.9 (C), 149.9 (C), 149.1 (C), 137.0 (CH), 136.8 (CH), 
132.0 (2CH), 131.3 (C), 129.5 (CH), 128.5 (C), 127.4 (C), 122.0 (CH), 118.8 (CH), 113.7 
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(2CH), 112.6 (CH), 112.2 (CH), 56.0 (CH3), 55.9 (CH3), 55.1 (CH3), 44.5 (CH2), 37.2 (CH2), 
31.3 (CH2). IR (neat, ν/cm-1): 3375 (w), 2981 (s), 1655 (m), 1602 (m), 1509 (s), 1446 (m), 1252 
(s), 1176 (m), 1139 (s), 1080 (m), 1019 (m), 959 (m), 833 (s), 738 (m), 620 (m). HR-MS (TOF-
AP+) calculated for C24H28N3O4 422.2080, found 422.2079.  
N-(3-(1H-Imidazol-1-yl)propyl)-3,6,7-trimethoxyphenanthrene-9-carboxamide, 16: In 
analogy to the preparation of 15, methyl 3,6,7-trimethoxyphenanthrene-9-carboxylate (9, 700 
mg, 2.15 mmol) was converted into the target compound 16 (730 mg, 1.74 mmol, 81%) which 
was obtained as a yellow waxy solid. 
1H-NMR (400 MHz, CDCl3): δ/ppm 7.71 (s, 1H), 7.65 (s, 1H), 7.63 (d, J = 2.5 Hz, 1H), 7.61 
(d, J = 8.8 Hz, 1H), 7.50 (s, 1H), 7.49 (s, 1H), 7.10 (dd, J = 8.7, 2.4 Hz, 1H), 7.06 (t, J = 5.9, 5.9 
Hz, 1H), 6.99 (t, J = 1.1 Hz, 1H), 6.93 (t, J = 1.3 Hz, 1H), 4.03 (s, 3H), 4.01 (t, J = 6.8 Hz, 2H), 
3.97 (s, 3H), 3.92 (s, 3H), 3.43 (app q, J = 6.8 Hz, 2H), 2.07 (p, J = 6.8 Hz, 2H).  13C-NMR (100 
MHz, CDCl3): δ/ppm 170.5 (C), 159.2 (C), 149.6 (C), 149.1 (C), 137.2 (CH), 131.9 (C), 130.7 
(CH), 129.4 (CH), 129.1 (C), 124.8 (C), 124.7 (CH), 124.2 (C), 124.1 (C), 118.9 (CH), 115.9 
(CH), 106.4 (CH), 103.7 (CH), 103.2 (CH), 55.9 (CH3), 55.8, (CH3), 55.5 (CH3), 44.8 (CH2), 
37.2 (CH2), 31.2 (CH2). IR (neat, ν/cm-1): 3259 (broad), 2939 (m), 1618 (m), 1522 (s), 1508 (s), 
1473 (s), 1270 (s), 1228 (s), 1206 (s), 1158 (m), 1033 (m), 832 (w), 734 (w). HR-MS (TOF 
AP+) calculated for C24H26N3O4 420.1923, found 420.1921. 
 (E)-N-(3-(1H-Imidazol-1-yl)propyl)-2-(3,4-dimethoxyphenyl)-3-(4-methoxyphenyl)prop-2-
en-1-amine, 17: To a solution of (E)-N-(3-(1H-imidazol-1-yl)propyl)-2-(3,4-dimethoxyphenyl)-
3-(4-methoxyphenyl)acryl-amide (15, 500 mg, 1.19 mmol) in dry THF (10 mL, 0.12 M) was 
added lithium aluminium hydride (LAH, 200 mg, 5.26 mmol) in portions at room temperature. 
After 2 hours the reaction mixture was carefully quenched by addition of ethyl acetate (1 mL) 
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and water (3 mL). The resulting emulsion was filtered through a pad of celite (ca. 10 g) and 
washed with ethyl acetate (30 mL). The resulting pale-yellow solution was evaporated to dryness 
yielding a yellow oil that was purified by column chromatography (20-40% EtOAc/hexanes). 
The desired product 17 was obtained as a colorless oil that solidified upon standing (445 mg, 
1.09 mmol, 92%).  
1H-NMR (400 MHz, CDCl3): δ/ppm 7.40 (s, 1H), 7.33 – 7.29 (m, 2H), 7.06 – 7.03  (m, 2H), 
7.02 (s, 1H), 6.92 – 6.86 (m, 3H), 6.82 (s, 1H), 6.77 (s, 1H), 3.96 (t, J = 6.9 Hz, 2H), 3.91 (s, 
3H), 3.89 (s, 3H), 3.82 (s, 3H), 3.75 (s, 2H), 2.54 (t, J = 6.6 Hz, 2H), 1.82 (p, J = 6.8 Hz, 2H). 
13C-NMR (100 MHz, CDCl3): δ/ppm 158.6 (C), 149.0 (C), 148.7 (C), 138.3 (C), 137.2 (CH), 
134.5 (C), 130.0 (2CH+C), 129.4 (CH), 129.1 (CH), 118.9 (CH), 118.7 (CH), 113.8 (2CH), 
111.2 (CH), 109.9 (CH), 56.0 (2CH3), 55.3 (CH3), 48.3 (CH2), 45.8 (CH2), 44.6 (CH2), 31.1 
(CH2). IR (neat, ν/cm-1): 2935 (w), 2836 (w), 1670 (m), 1604 (m), 1509 (s), 1463 (m), 1246 (s), 
1176 (m), 1143 (m), 1024 (s), 812 (m), 765 (m), 731 (s), 683 (m), 531 (m). HR-MS (TOF-AP+) 
calculated for C24H30N3O3 408.2287, found 408.2285. 
3-(1H-Imidazol-1-yl)-N-((3,6,7-trimethoxyphenanthren-9-yl)methyl)propan-1-amine, 18: In 
analogy to the preparation of compound 17, N-(3-(1H-imidazol-1-yl)propyl)-3,6,7-
trimethoxyphenanthrene-9-carboxamide (16, 500 mg, 1.19 mmol) was converted to the target 
compound that was isolated as a waxy solid (454 mg, 1.12 mmol, 94%). 
1H-NMR (400 MHz, CDCl3): δ/ppm 7.80 (s, 1H), 7.75 (d, J = 2.4 Hz, 1H), 7.68 (d, J = 8.7 Hz, 
1H), 7.40-7.45 (m, 2H), 7.36 (s, 1H), 7.13 (dd, J = 8.7, 2.4 Hz, 1H), 6.96 (t, J = 1.1 Hz, 1H), 6.78 
(t, J = 1.1 Hz, 1H), 4.04 (s, 2H), 4.02 (s, 3H), 3.97 (s, 3H), 3.94 (s, 3H), 3.91-3.95 (m, 2H), 2.64 
(t, J = 6.7 Hz, 2H), 1.87 (app p, J = 6.7 Hz, 2H). 13C-NMR (100 MHz, CDCl3): δ/ppm 158.1 
(C), 149.2 (C), 148.7 (C), 137.1 (CH), 130.8 (C), 130.5 (C), 129.9 (CH), 129.3 (CH), 126.2 (C), 
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125.7 (C), 124.9 (C), 124.6 (CH), 118.9 (CH), 115.5 (CH), 104.8 (CH), 103.8 (CH), 103.7 (CH), 
56.0 (CH3), 55.9 (CH3), 55.5 (CH3), 52.5 (CH2), 46.3 (CH2), 44.7 (CH2), 31.5 (CH2). IR (neat, 
ν/cm-1): 3002 (w), 2935 (w), 2832 (w), 1609 (s), 1523 (s), 1509 (s), 1467 (s), 1269 (s), 1205 (s), 
1161 (m), 1070 (m), 1032 (m), 834 (w), 731 (m). HR-MS (TOF AP+) calculated for C24H28N3O3 
406.2131, found 406.2137. 
3,6,7-Trimethoxy-11,12,13,14,14a,15-hexahydro-9H-dibenzo[f,h]pyrido[1,2-b]isoquinolin-
15-ol (19a and 19b): To a solution of 3,6,7-trimethoxy-12,13,14,14a-tetrahydro-9H-
dibenzo[f,h]pyrido[1,2-b]isoquinolin-15(11H)-one (13, 250 mg, 0.64 mmol) in dry THF (10 mL, 
0.06 M) was slowly added lithium aluminium hydride (73 mg, 1.92 mmol, 3.0 equiv.). After 
stirring at room temperature for 1 h the mixture was carefully quenched by addition of ethyl 
acetate (1 mL) and water (1 mL). Filtration over a pad of celite (ca. 5 g) and elution with ethyl 
acetate (20 mL) yielded after evaporation the crude mixture of 19a and 19b (213 mg, 0.54 mmol, 
85%) in a 1:2 ratio as evidenced by 1H-NMR. The separation of this mixture was accomplished 
by preparative thin layer chromatography (2 runs) using EtOAc/hexanes (30:70) as solvent 
system.  
Rac-(14aR,15S)-3,6,7-Trimethoxy-11,12,13,14,14a,16-hexahydro-9H-dibenzo[f,h]pyrido-
[1,2-b]isoquinolin-15-ol, 19a: 
1H-NMR (700 MHz, CDCl3): δ/ppm 8.30 (d, J = 9.1 Hz, 1H), 7.82 (d, J = 2.6 Hz, 1H), 7.80 (s, 1H), 7.21 
(dd, J = 9.1, 2.5 Hz, 1H), 6.69 (s, 1H), 4.99 (d, J = 5.6 Hz, 1H), 4.10 (s, 3H), 4.01 (s, 3H), 3.93 (d, J = 
15.0 Hz, 1H), 3.89 (s, 3H), 3.03 (br s, 1H), 2.44 (br s, 2H), 2.10 (s, 1H), 1.83 (d, J = 12.7 Hz, 1H), 1.75 
(d, J = 14.3 Hz, 1H), 1.64 (d, J = 13.8 Hz, 1H), 1.41 (q, J = 12.7 Hz, 1H). 3 Resonances were not 
observed due to broadening effects. 13C-NMR (176 MHz, CDCl3): δ/ppm 157.7 (C), 149.4 (C), 148.9 
(C), 131.1 (C), 127.5 (CH), 124.1 (C), 124.0 (C), 123.8 (C), 114.8 (CH), 104.6 (CH), 103.7 (CH), 103.2 
(CH), 70.3 (CH), 65.5 (CH), 55.9 (CH3), 55.8 (CH3), 55.5 (CH3), 54.5 (CH2), 23.3 (CH2). 5 Resonances 
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were not observed (2 C, 3 CH2). IR (neat, ν/cm-1): 3300 (broad), 2936 (m), 1732 (w), 1615 (m), 1514 (s), 
1471 (s), 1426 (m), 1262 (s), 1235 (m), 1206 (s), 1172 (m), 1147 (m), 1039 (s), 914 (m), 840 (m), 731 
(m). HR-MS (ESI-TOF+) calculated for C24H28NO4 394.2018, found 394.2028.  
Rac-(14aR,15R)-3,6,7-Trimethoxy-11,12,13,14,14a,16-hexahydro-9H-dibenzo[f,h]pyrido-
[1,2-b]isoquinolin-15-ol, 19b: 
1H-NMR (600 MHz, CDCl3): δ/ppm  8.35 (d, J = 9.0 Hz, 1H), 7.68 (d, J = 2.6 Hz, 1H), 7.50 (s, 1H), 
7.21 (dd, J = 9.0, 2.5 Hz, 1H), 5.91 (s, 1H), 4.59 (d, J = 2.5 Hz, 1H), 4.07 (s, 3H), 4.02 (s, 3H), 3.71 (s, 
3H), 2.84-3.00 (m, 2H), 2.80 (d, J = 14.9 Hz, 1H), 2.24 (qd, J = 13.3, 3.8 Hz, 1H), 2.07 (d, J = 11.2 Hz, 
1H), 1.90-2.00 (m, 2H), 1.82 (q, J = 13.1 Hz, 1H), 1.73 (d, J = 13.1,  Hz, 1H), 1.67 (d, J = 12.2 Hz, 1H), 
1.27-1.35 (m, 1H). 13C-NMR (151 MHz, CDCl3): δ/ppm 157.4 (C), 148.5 (C), 148.3 (C), 130.4 (C), 
127.8 (C), 126.8 (CH), 124.7 (C), 124.0 (C), 123.5 (2C), 111.4 (CH), 104.0 (CH), 102.9 (CH), 102.5 
(CH), 66.5 (CH), 62.5 (CH), 56.7 (CH2), 55.6 (CH3), 55.4 (CH3), 55.3 (CH3), 55.2 (CH2), 27.0 (CH2), 
25.1 (CH2), 24.1 (CH2). IR (neat, ν/cm-1): 3184 (broad), 2938 (m), 1743 (w), 1611 (m), 1534 (m), 1511 
(s), 1470 (s), 1424 (m), 1257 (s), 1204 (s), 1171 (s), 1127 (m), 1042 (s), 910 (m), 839 (m), 730 (s). HR-
MS (ESI-AP+) calculated for C24H28NO4 394.2018, found 394.1990. X-ray analysis: xxxx 
 
4.1. Biological Evaluation 
4.2.1. Cells culture  
Hepatocellular carcinoma cell lines (Huh7, FOCUS, Hep3B, HepG2 and Mahlavu), human 
breast carcinoma cells (MCF7) and human colon carcinoma cells (HCT116) were grown in 
Dulbecco's Modified Eagles Medium (DMEM) supplemented with 10% fetal bovine serum 
(GIBCO, Invitrogen), 1% non-essential amino acids (GIBCO, Invitrogen) and SNU-475 were 
grown in RPMI-1640 media (Invitrogen GIBCO) supplemented with 10% FBS, 2 mM L-
glutamine. All media contained 100 units/ml penicillin and streptomycin and cells were 
maintained at 37 ˚C in a humidified incubator under 5% CO2. 
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4.2.2. NCI-60 Sulforhodamine B Assay 
Cells were plated in 96-well plates (HCT116 – 3000, Huh7, Hep3B, HepG2, MCF-7 –2000, 
Mahlavu, FOCUS, SNU475-1000 cells per well) and grown for 24 hours in an incubator. The 
compounds were dissolved in DMSO and were prepared 20mM stock solution. The compounds 
were tested starting from 40 µM to 2,5 µM in triplicates. The compounds, which were below 2,5 
µM, were tested starting from 2,5 µM to 0,03 µM. After 72h of incubation, cells were fixed 
using 10% (v/v) trichloroacetic acid (MERCK) for an hour. The fixed plates were dried and 
samples were stained with sulforhodamine B (SRB) solution (50 µl of a 0.4% (m/v) of SRB in 
1% acetic acid solution) for 10 min. The excess amount of SRB dye was discarded by washing 
samples with 1% acetic acid and left for air-drying. The protein bound SRB dye was dissolved in 
10 mM Tris-base and its absorbance was measured with 96-well plate reader at 515 nm. The IC50 
values were calculated based on DMSO control normalization. 
 
4.2.3. Real-time cell growth surveillance by electronic sensing (RT-CES) 
Real-time cell growth analysis was performed using the the xCELLigence System (Roche 
Applied Sciences). The Huh7 (2000) and Mahlavu (1000) cells were plated in 96 well E plates. 
In proliferation step, the cellular growth was analyzed with cell index measurements in 30 min 
intervals. After 24 h of incubation, when cells reach the log growth phase, they were treated with 
Boehmeriasin derivatives compounds starting from 1 µM and 2 folds serial diluted 4 times. The 
cell index values (CI) were initially monitored every 10 min for 24 h and then CI were recorded 
in 30 min intervals. After 72 h of incubation, the cellular growth inhibition was calculated based 
on the DMSO normalization. 
 
4.2.4 DCHF-DA Staining for ROS detection  
Huh7 cells were plated into 6 well plates and treated with 1 µM Boehmeriasin derivatives. After 
treatment, samples were washed with PBS 3 times, they were incubated with DCFH-DA assay 
solution for 15 min in humidified chamber at 37 ˚C. The solution was aspirated and cells were 
washed with PBS 2 times. The staining was analyzed with fluorescence microscope.  
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4.2.5. Western Blot Analysis 
Huh7 and Mahlavu cells were treated with the Boehmeriasin derivatives compounds (IC100 
concentrations) or with DMSO control for 48 hours. After incubation period, the cells were 
collected with scraper, their total proteins were isolated and protein concentrations were 
calculated with Bradford assay. 20-50 µg from all proteins were loaded to Bis-Tris gel and 
western blot was performed with Novex® NuPAGE® Bis-Tris Electrophoresis system. Then the 
proteins were transferred to nitrocellulose membrane via XCell IITM Blot Module. Cyclin-B1 
(554177, BD), Cdc2/Cdk1 (PC25, Calbiochem), PARP (9532, Cell Signaling), Cyclin E (CC05, 
Calbiochem), Cdk2 (sc6248, Santa Cruz), phosphor ASK1 (3765, Cell Signaling), phosphor 
SAPK/JNK ( 9251, Cell Signaling), phosphor AKT ( 9275, Cell Signaling) and AKT (9272, Cell 
Signaling) antibodies were used in 1:100 to 1:500 5% BSA-TBS-T. β-actin (#A5441, Sigma)  
and Calnexin (C4731, Sigma) antibodies were used in 1:1000 concentration for equal loading. 
 
4.2.6. Immunofluorescence Assay  
Huh7 and Mahlavu cells were seeded in 6 well plates on coverslips. After 24 hours, cells were 
treated with the 1 µM Boehmeriasin derivatives for 72 hours. Camptothecin was used as positive 
control for cytochrome c activity. DMSO control were given to cells in the same amount of the 
compounds. After the incubation period, cells were fixed with ice-cold methanol for 15 min. The 
cytochrome c primary antibody (Santa Cruz, 1:100 in 0,1 % TBS-Tween) were applied for 1 
hour. FITC conjugated secondary antibody (Santa Cruz, 1:200 in 0,1 % TBS-Tween) were 
applied for 1 hour. The cells were mounted with UltraCruz DAPI mounting medium and photos 
were taken with fluorescence microscopy.  
 
4.2.7. Flow Cytometry for Cell Cycle Analysis 
Huh7 and Mahlavu cells were seeded onto 100 mm culture dishes. After 24 h, cells were treated 
with the 1 µM Boehmeriasin derivatives. After 24 h, 48 h and 72 h of incubation, cells were fixed 
with ice-cold 70% ethanol for 3 hours at -20 °C. Cell cycle analysis was carried out by PI 
(Propidium Iodide) staining using MUSE Cell Analyzer according to the manufacturer’s 
recommendations (Millipore). 
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